2023 annual financial data
CRISPR Therapeutics 2023 Financial results
Direct answer
Revenue was 370,000,000 USD.
Operating income was -222,538,000 USD and net income was -153,610,000 USD.
Operating cash flow was -260,375,000 USD.
Get free CRISPR Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 370,000,000 USD
- Operating income
- -222,538,000 USD
- Net income
- -153,610,000 USD
- Operating cash flow
- -260,375,000 USD
Explore related company data
View all 2023 financial metricsView RevenueView Operating incomeView Net incomeView Operating cash flowView Revenue growthView Operating income growthView Net income growthView Operating cash flow growthView Operating marginView Net marginView Operating cash flow marginView all CRISPR Therapeutics financial years